PIVOT-09

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Feb 12, 2019 → Jun 10, 2024

Cited window

Feb 12, 2019 → Jun 10, 2024

Retrieved

Oct 30, 2026

Title

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma

Registry

NCT03729245

Study IDs

17-214-09 · CA045002 (Bristol-Myers Squibb Protocol ID)

Sponsor

Nektar Therapeutics

Collaborators

Bristol-Myers Squibb

Design

Phase 3 · Interventional, randomized, parallel

Status

Terminated

Enrollment

623 actual

Registered

2018-11-02

Start

2018-12-18 actual

Primary completion

2022-01-07 actual

Primary endpoint

Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition are a selective set of public discussions, not a representative assessment of HCP opinion.
• –Discussion omitting the trial name or using other shorthand may be absent. Some potentially relevant discussions were not read, and some passages were not fully assessed, so additional viewpoints may be missing.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The presentation and publication summaries relayed by a speaker are not independent analyses by the speaker. Circulation through reposts does not establish additional authors’ endorsement.
• –The posts often omit numerical estimates, risk-population details and statistical qualifications; the tentative subgroup statement is especially limited.

How reports are built and checked: Methods.

Last checked for new commentary Oct 30, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "PIVOT-09" (NCT03729245), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "pivot-09-03729245". If you cannot make requests, read https://www.erudio.com/reports/pivot-09-nct03729245.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT03729245", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct03729245 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/pivot-09-nct03729245.json
curl https://www.erudio.com/reports/pivot-09-nct03729245.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "pivot-09-03729245" })